High early mortality after nephrostomy in metastatic cancer
Author Information
Author(s): Amandeep Dosanjh, Benjamin Coupland, Jemma Mytton, Dominic Stephen King, Harriet Mintz, Anna Lock, Veronica Nanton, Param Mariappan, Nigel Trudgill, Prashant Patel
Primary Institution: University of Birmingham Institute of Cancer and Genomic Sciences
Hypothesis
What are the outcomes of percutaneous nephrostomy in patients with metastatic cancer?
Conclusion
Nephrostomy in patients with metastatic cancer often leads to high mortality and complications, with minimal survival benefit.
Supporting Evidence
- 1 in 15 patients died within 14 days of nephrostomy.
- 1 in 6 patients died within 30 days.
- 25.4% received subsequent chemotherapy.
- 43.8% had subsequent abdominopelvic surgery.
- 24.5% of patients had at least one direct complication of nephrostomy.
Takeaway
This study found that many patients who get a nephrostomy for cancer die soon after, and it doesn't really help them live longer or feel better.
Methodology
Retrospective observational study using Hospital Episode Statistics data from 2010 to 2019.
Potential Biases
Potential bias due to the administrative nature of the data and lack of patient identification.
Limitations
The study lacks biochemical or histopathological data and cannot control for all potential confounding variables.
Participant Demographics
58% male, 51% over 70 years old, 57.7% had no relevant comorbidities.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website